Industry News
Pharmaceutical Industry News
United’s share price surged by…
United's share price surged by more than 33% by Tuesday afternoon with what the company's SVP of product development Peter Smith called "overwhelmingly positive" phase 3 results in idiopathic pulmonary fibrosis.
Dr. Jeffrey Allen discusses the…
Dr. Jeffrey Allen discusses the need for shared clinical language, patient input and new treatment approaches for chronic inflammatory demyelinating polyneuropathy.
In a Q&A for Fierce Pharma…
In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Biles discussed the importance of empathy in her work and her vision for a more all-encompassing depiction of the patient experience in pharma ads.
Ionis has hit a “home run,”…
Ionis has hit a “home run,” according to analysts at Citi, with data in two phase 3 trials that show the ability of Tryngolza to reduce triglycerides and acute pancreatitis events in individuals with severe
Verquvo failed to deliver a…
Verquvo failed to deliver a composite cardiovascular benefit for certain patients with heart failure, with investigators noting seemingly divergent results on two key measures.
While a recent head-to-head trial…
While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with Zepbound-topping data in another
After musing on a fall IPO just…
After musing on a fall IPO just last week, Stada is instead being picked up by CapVest Partners in a deal that reportedly values the business at around 10 billion euros ($11.6 billion), according to
Is ‘Microdosing’ Accutane Effective?
Chapped lips, peeling skin, nosebleeds — the drug treats acne, but its side effects can be miserable. Will a lower dose help?
The U.S. subsidiary of India’s…
The U.S. subsidiary of India’s Unichem Pharmaceuticals voluntarily recalled one lot of the muscle relaxant cyclobenzaprine hydrochloride after a labeling snafu.
The FDA has approved a…
The FDA has approved a once-weekly subcutaneous maintenance dose of Leqembi in an autoinjector, dubbed Leqembi IQLIK, which Eisai has hailed as a key milestone in its quest to grow the reach of the Alzheimer's disease
Wegovy’s mechanism of action could…
Wegovy's mechanism of action could be ideal for patients with more moderate disease, according to gastroenterologists and hepatologists surveyed by Spherix.
Flying high after an FDA approval…
Flying high after an FDA approval four months ago to treat generalized myasthenia gravis, Johnson & Johnson’s much-touted Imaavy has taken a hit, coming up short as part of a combination therapy in a rheumatoid
Pfizer is taking a curtain call…
Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM).
Amid a growing push for more…
Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia
The University of Michigan is…
The University of Michigan is suing AstraZeneca over claims that the British drugmaker continues to market and sell FluMist despite not renewing a key contract with the school that was crucial to the vaccine's development.
Learn more about how our enhanced…
Learn more about how our enhanced Consumer Audiences can help you achieve more efficient DTC campaigns with audiences created using our synthetic trends methodology.
Patients in the U.S. now have…
Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide).
The Leukemia & Lymphoma…
The Leukemia & Lymphoma Society is marking Blood Cancer Awareness Month by rebranding and rolling out its first national advertising campaign in more than a decade.
The private equity-owned company…
The private equity-owned company held off on a previously planned IPO in March due to market volatility.
After Maze Therapeutics opted not…
After Maze Therapeutics opted not to participate in the National Advertising Division’s self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex Pharmaceuticals is being escalated to federal authorities.